Top 100 Products in FY2011: Pronounced Growth for ARB Combinations with Declining Sales of Monodrugs

A survey conducted by Jiho, Inc. of domestic drug makers’ settlements of accounts for FY2011 and other published data shows that the angiotensin II receptor blocker (ARB) Blopress (candesartan) retained its No. 1 position among the top 100 ethical drugs...read more